PubMed Health⌕ Search

PubMed · 6369924

Immunosuppressant therapy.

Abstract

In this chapter, an attempt has been made to discuss the major immunosuppressant agents in use today as well as some of those whose future is as yet undecided. Obviously, not every immunosuppressive modality could be included in this limited space. However, we have endeavored to include agents of practical and theoretical importance to the practicing physician. The therapies discussed here are all hampered by significant degrees of toxicity, which compromises their usefulness and limits their potential. The decision to begin therapy with these agents must be made carefully, and it is incumbent upon the physician to include the patient and patient's family in this process. In many cases, these choices can be based on well-controlled trials in which efficacy has been established. Unfortunately, for many immunologically mediated processes no such studies are available, or those that have been reported are flawed. In such cases, decisions become increasingly difficult. One must then weigh the potential adverse effects of the agent against the possible long-term consequences of witholding such treatment. We can only hope that the continued study of these diseases and the immunosuppressant agents in concert with the development of new, less toxic therapies will make these choices less difficult in the future.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Katz. 1984. Immunosuppressant therapy.. https://pubmed.ncbi.nlm.nih.gov/6369924/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗